Stockscreener 앱 받기
2.63
3.54%
0.09
시간 외 거래:
2.46
-0.17
-6.46%
Rafael Holdings Inc 주식(RFL)의 최신 뉴스
RFL Q1 2025 Earnings: Net Loss of $0.37 Per Share, Stock Rises 5.66%Earnings Beat Alert - newsline.com
RFL Q1 2025 Earnings: Loss Per Share of -$0.37 as Stock Rises 5.66%Net Income Trends - newsline.com
RFL Q1 2025 Earnings: Net Loss of $0.37 per Share as Holding Company Maintains Strategic FocusMargin Expansion Trends - newsline.com
Rafael Holdings Releases Q3 2026 Financial Results - AlphaStreet
Rafael Flat on Q3 Figures - TradingView
Rafael Holdings narrows Q3 loss to $(0.08) per share - scanx.trade
Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary - TradingView
Rafael Holdings (NYSE: RFL) posts Q3 2026 loss as it funds Trappsol Cyclo trial - Stock Titan
Rafael Holdings reports Q3 FY2026 net loss of $4.2M; cash $30.5M; NDA expected H2 2026 - TradingView
RFL: Pivotal Phase 3 trial completed; NDA submission and commercial transition expected in H2 2026 - TradingView
[8-K] Rafael Holdings, Inc. Reports Material Event - Stock Titan
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results - The Manila Times
Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial - Quiver Quantitative
BRIEF-Rafael Holdings Q3 Net Income USD -2.899 Million - TradingView
Rare disease trial milestone: Rafael plans 2026 NPC drug filing - Stock Titan
Rafael Holdings (RFL) completes Phase 3 TransportNPC trial - grafa.com
Rafael Holdings, Inc. Announces Completion Of Last Patient Last Visit For Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C - marketscreener.com
Rafael Holdings Completes Pivotal Phase 3 TransportNPC Study - TipRanks
Rafael Holdings completes phase 3 NPC disease trial enrollment - Investing.com
Rafael Holdings completes phase 3 NPC disease trial enrollment By Investing.com - Investing.com Canada
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C - The Manila Times
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 ... - Enidnews.com
Rafael Holdings Nears Finish Line in Rare Disease Race, Eyes Commercial Future - BriefGlance
Rafael Holdings concludes Phase 3 TransportNPC™ trial for NPC - grafa.com
RFL Q1 2025 Earnings: Net Loss Reported as Company Advances Strategic InitiativesQuarterly Earnings - newsline.com
Rafael Holdings (RFL) Surges 5% as Momentum Builds; Key Resistance in SightStop Hunt - newsline.com
RFL Q1 2025 Earnings: Widening Losses Amid Continued Development StageForward Guidance Trends - newsline.com
RFL Q1 2025 Earnings: Wider Loss Stems From Continued Clinical InvestmentAnalyst Consensus Shift - The Legal Advocate
Rafael Holdings (RFL) Q1 2025 Earnings: Net Loss of $0.37 Per Share as Stock Slightly DeclinesFinancial Health Score - The Legal Advocate
RFL Q1 2025 Earnings: Narrowing Losses Amid No Revenue – Stock Edges HigherDividend Increase Stocks - newsline.com
RFL Q1 2025 Earnings: Net Loss of $0.37 per Share as Pre‑Revenue Development ContinuesEarnings Surprise Report - The Legal Advocate
Rafael Holdings (RFL) Edges Higher: Testing Key Resistance After 2.19% GainLinear Regression - The Legal Advocate
Rafael Holdings Inc. Q1 2025 Earnings: Negative EPS Persists as Stock Shows Modest GainsGuidance Revision Trend - The Legal Advocate
Rafael Holdings Inc. (RFL) Q1 2025 Earnings: Net Loss Widens Amid Minimal Operating Revenue - newsline.com
Rafael Holdings (RFL) Shows Modest Uptick as Shares Test Key Resistance LevelsPut Flow Alert - The Legal Advocate
Rafael Holdings (RFL) Sees Modest Uptick, Testing Key Resistance at $1.41Community Watchlist Picks - Newser
Rafael Holdings (RFL) Q1 2025 Results Meet Expectations — Revenue $N/ARevenue Beat Analysis - The Legal Advocate
Ceasefire on paper, war in the courts: Why the Lopez feud is far from over - Rappler
MSN Money - MSN
TradingKey - TradingKey
Piki sues Lopez majority bloc for contempt of court - Inquirer.net
Armani Group Partners With Rafael Nadal’s Firm on Luxury Residences in Marbella - Yahoo Finance Singapore
CAEP (CantorEquity) reports quarterly earnings with key metrics pending; market monitors for additional disclosure.Book Value Growth - The Legal Advocate
CYTH Stock Insider Trading Activity - Quiver Quantitative
Floor & Decor Holdings President Acquires 39% More Stock - Yahoo Finance
How Rafael Holdings (RFL) performance reflects its true potential (Institutional Demand) 2026-05-07Social Buy Zones - Newser
Businesses on the move in Marin, Napa, Solano, Sonoma and Mendocino counties: April 30 report - The Press Democrat
Ekso Bionics: Q1 Earnings Snapshot - KTVB
Rafael Holdings Insider Ups Holding By 1,810% During Year - Yahoo Finance
RFL Price Today: Rafael Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
This R.E.A. Holdings Insider Increased Their Holding By 34% Last Year - Yahoo Finance
Rafael unit secures MIT license for Alzheimer’s treatment By Investing.com - Investing.com Australia
Rafael unit secures MIT license for Alzheimer’s treatment - Investing.com
Rafael Holdings Secures Exclusive MIT Patent License for Cyclodextrins in ApoE4-Positive Alzheimer’s Treatment - Minichart
Rafael Holdings expands Alzheimer’s portfolio with MIT license - TipRanks
Rafael Holdings (NYSE: RFL) secures exclusive MIT patent license for ApoE4 Alzheimer’s use - Stock Titan
MIT grants Rafael exclusive rights for Alzheimer’s therapy in ApoE4 patients - Stock Titan
0.73%
자본화:
|
볼륨(24시간):